0001209191-23-006275.txt : 20230202
0001209191-23-006275.hdr.sgml : 20230202
20230202171533
ACCESSION NUMBER: 0001209191-23-006275
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230131
FILED AS OF DATE: 20230202
DATE AS OF CHANGE: 20230202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gano Kyle
CENTRAL INDEX KEY: 0001567160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 23582222
MAIL ADDRESS:
STREET 1: NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-31
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001567160
Gano Kyle
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Business Development Off
Common Stock
2023-01-31
4
S
0
1541
109.9847
D
112820
D
Sale of 1,541 shares of common stock issued upon vesting of 2,926 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,385) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Includes an aggregate of 262 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
/s/ Darin Lippoldt, Attorney-in-Fact
2023-02-02